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Abstract 
Background: Despite remarkable success obtained with current malaria vector control strategies in the last 15 years, 
additional innovative measures will be needed to achieve the ambitious goals for malaria control set for 2030 by the 
World Health Organization (WHO). New tools will need to address insecticide resistance and residual transmission as 
key challenges. Endectocides such as ivermectin are drugs that kill mosquitoes which feed on treated subjects. Mass 
administration of ivermectin can effectively target outdoor and early biting vectors, complementing the still effective 
conventional tools. Although this approach has garnered attention, development of ivermectin resistance is a poten-
tial pitfall. Herein, we evaluate the potential role of xenobiotic pumps and cytochrome P450 enzymes in protecting 
mosquitoes against ivermectin by active efflux and metabolic detoxification, respectively.
Methods: We determined the lethal concentration 50 for ivermectin in colonized Anopheles gambiae; then we used 
chemical inhibitors and inducers of xenobiotic pumps and cytochrome P450 enzymes in combination with ivermec-
tin to probe the mechanism of ivermectin detoxification.
Results: Dual inhibition of xenobiotic pumps and cytochromes was found to have a synergistic effect with ivermec-
tin, greatly increasing mosquito mortality. Inhibition of xenobiotic pumps alone had no effect on ivermectin-induced 
mortality. Induction of xenobiotic pumps and cytochromes may confer partial protection from ivermectin.
Conclusion: There is a clear pathway for development of ivermectin resistance in malaria vectors. Detoxification 
mechanisms mediated by cytochrome P450 enzymes are more important than xenobiotic pumps in protecting mos-
quitoes against ivermectin.
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Background
Since the turn of the century, significant advances have 
been made against malaria; the global malaria mortality 
rate has reduced by more than 50%, saving more than 
6.8 million lives [1, 2]. Two vector control measures are 
mainly responsible for this success, (1) the use of insec-
ticide-treated nets and (2) indoor residual spraying, both 
of which are insecticide-based and home-centered [3]. 
The continuous use and reliance on insecticides has put 
selective pressure on the mosquitoes, radically chang-
ing the vector species’ distribution and behavior [4]. 
This allows malaria transmission to continue by shifting 
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to times and spaces unprotected by the current vector 
control measures, most noticeably early biting and/or 
outdoor biting [5]. Moreover, the selection pressure has 
yielded mosquito populations that are resistant to the 
current insecticides used in malaria vector control [6].
The new challenges in vector control urgently call for 
the development of new tools to circumvent them [7]. 
One of the proposed tools currently under evaluation is 
the use of endectocides [8]. Endectocides are antipar-
asitic drugs with activity against endoparasites and 
ectoparasites such as mosquitoes which feed on treated 
humans or animals. Importantly, endectocides can target 
exophilic and exophagic vectors, tackling the problem of 
residual transmission, while perfectly complementing the 
indoor vector control measures [9].
Owing to its excellent safety profile and activity against 
most malaria vectors, ivermectin is the leading endecto-
cide candidate for malaria control [10, 11]. In addition, 
ivermectin is used extensively for the control of neglected 
tropical diseases (NTDs) that overlap with malaria in 
endemic areas, potentially increasing the cost-effective-
ness of implementing ivermectin mass drug administra-
tion (MDA) [12, 13].
Several of the effects ivermectin has on malaria vectors 
point towards a low risk and slow speed for the devel-
opment of resistance. These include (1) its mechanism 
of action, agonizing glutamate-gated chloride channels, 
which differs from all currently approved public health 
insecticides [14]; (2) direct delivery to the midgut with 
a blood meal that can bypass resistance associated with 
cuticular mechanisms [15]; and (3) marked reduction in 
fertility and fecundity of malaria vectors exposed to sub-
lethal concentrations [16, 17]. Although the development 
of ivermectin resistance in malaria vectors may take a 
long time, it is inevitable, as it has already been reported 
in other arthropods [18]. Moreover, considering that 
ivermectin MDA for NTDs has been ongoing for the past 
30  years, these could have potentially exposed malaria 
vectors to mostly sublethal ivermectin concentrations 
that could enhance the process of resistance development 
[19]. Therefore, it is important to have an early and thor-
ough understanding of potential mosquito detoxification 
mechanisms for ivermectin. This will be crucial for early 
development of approaches that could delay, counter, or 
detect ivermectin resistance.
Herein, we evaluated the potential detoxification mech-
anisms involved in the response to ivermectin in the 
Anopheles gambiae s.s. mosquito. We were mainly inter-
ested in two general mechanisms of detoxification: (1) 
metabolic detoxification mediated by enzymes, specifi-
cally cytochrome P450 enzymes (CYPs), and (2) detoxi-
fication by excretion facilitated by ATP binding cassette 
(ABC) transporters, specifically P-glycoprotein (P-gp). 
The increased activity of CYPs leads to increased biodeg-
radation of the toxins, while increased activity of P-gp 
leads to increased excretion of xenobiotics. Both mech-
anisms reduce the toxic effects of the compounds by 
decreasing the insects’ systemic exposure to them [20]. 
Both detoxification mechanisms have been implicated in 
resistance to insecticides used for the control of malaria 
vectors, with metabolic detoxification being the most 
common mechanism [21, 22]. Elevated levels of CYPs, 
esterases, and glutathione S-transferases (GSTs) are asso-
ciated with resistance to different classes of insecticides 
[22]. Though both mechanisms are known to contribute 
to ivermectin resistance in other arthropods, their poten-
tial contribution to ivermectin resistance in mosquitoes 
has not been thoroughly explored [23–25].
In this study, we assessed the interaction of different 
chemical inhibitors and inducers of CYP and P-gp with 
ivermectin in An. gambiae s.s. (Kilifi strain) mosquitoes. 
Our main questions were whether and how the inhibitors 




The experiments were conducted in two phases. In 
phase 1, an ivermectin dose-finding experiment was 
performed using triplicate batches of 50 female mos-
quitoes (3–5  days old) with the aim of identifying the 
10-day  LC50 of ivermectin for our colony (Fig.  1). The 
10-day period was chosen based on the minimum 
extrinsic incubation period of Plasmodium falcipa-
rum parasites, i.e. mosquitoes dying before 10 days are 
unlikely to become infectious [26]. We tested five dif-
ferent concentrations of ivermectin spanning ± 20–40% 
of the 5-day  LC50 described by Kobylinski et  al. [27], 
namely 4  ng/ml, 8  ng/ml, 12  ng/ml, 16  ng/ml, and 
20 ng/ml.
In phase 2, following the identification of a concen-
tration of ivermectin yielding about 50% mortality in 
10 days, we evaluated (1) the effect on mosquito mor-
tality of CYP and/or P-gp inhibitors and inducers alone 
at different concentrations and (2) the effect of combin-
ing ivermectin with different doses of CYP and/or P-gp 
inhibitors and inducers (Fig. 2).
For voriconazole, ritonavir, cobicistat, cyclosporine 
A, elacridar, and rifampicin, the concentrations 
tested were based on the maximum blood concentra-
tion reached in humans after a single dose (Cmax) as 
reported in the literature (Table 1). Four concentrations 
corresponding to Cmax, 75% Cmax, 50% Cmax and 25% 
Cmax were evaluated. Hereafter, Cmax concentration is 
referred to as A, 75% Cmax as B, 50% Cmax as C, and 25% 
Cmax as D.
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Given that mosquitoes were to be exposed in batches to 
the different drugs and combinations, the study was con-
sidered cluster-randomized, in which the batch exposed 
to any drug was the unit of randomization and the mos-
quito was the analysis unit. The sample size was adjusted 
for a cluster effect. A 50% increase in ivermectin-driven 
10-day mosquito mortality was considered of potential 
public health value. According to the method reported 
by Hayes and Bennett [28], using three replicas of 50 
mosquitoes per group gives the study 80% power at a 5% 
significance level to detect a 50% increase in 10-day mor-
tality from 50 to 75% by adding the synergist. This uses 
an intra-cluster correlation coefficient of 0.06 described 
before for mosquito colonies [29]. These calculations are 
confirmed using the formula of Gangnon and Kosorok 
[30], which shows a design effect of 3.34, with 70% pos-
sibility of observing mortality within 10 days.
Mosquitoes
Throughout the study we used an Anopheles gambiae 
s.s. Kilifi strain maintained in KEMRI–Wellcome Trust 
Research Programme insectary in Kilifi, Kenya. The 
colony was adapted to the insectary in 2011 from lar-
vae collected in Mbogolo, Kilifi county. The colony is 
fully insecticide-susceptible and is subjected to quarterly 
resistance monitoring using WHO tube tests.
The mosquitoes were maintained at 28  °C and 80% 
relative humidity at a 12-h light:12-h dark photoperiod. 
Adult mosquitoes were fed ad libitum 10% glucose solu-
tion via impregnated cotton wool, while larvae were fed 
TetraMin fish flakes.
Experimental drugs
Based on their mechanism of action in humans, vori-
conazole, ritonavir, and cobicistat were classified as 
dual CYP/P-gp inhibitors [18, 19], cyclosporine A and 
elacridar were classified as P-gp-specific inhibitors 
[37], and rifampicin was classified as a dual CYP/P-gp 
inducer [38]. The choice of inhibitors and inducers used 
in the present study was based on their ability to act 
as substrates for the CYP CYP3A4, which is the major 
enzyme involved in ivermectin metabolism in humans 
[39].
Ivermectin, voriconazole, ritonavir, cobicistat, cyclo-
sporine A, elacridar, and rifampicin were obtained 
from Sigma Aldrich (Spain). The active pharmacologi-
cal ingredients were dissolved in dimethyl sulfoxide 
(DMSO) to prepare stock solutions for all compounds. 
Aliquots of the prepared solutions were frozen at 
−20 °C. For each experiment, the stock solutions were 
diluted in phosphate-buffered saline (PBS) to achieve 
the desired concentration.
Membrane blood feeding
For blood feeding, we used certified drug-free cat-
tle blood defibrinated using the Reynold’s method [40]. 
Briefly, after blood collection, the blood was gently 
shaken for 5–10 min in a 250 ml glass bottle containing 
a copper wire arranged as an elongated spiral with two 
outer loops inside. The wire was then removed together 
with the fibrin that became bound to it [40]. The defi-
brinated blood was mixed with the drugs at appropriate 
concentrations to a total volume of 6  ml. In the case of 
the control group, the blood was mixed with PBS only.
Fifty 2–5-day-old blood-naïve female mosquitoes 
were transferred from stock cages to mosquito hold-
ing cups (1000  cm3) and starved of water and glucose 
for 6–8 h before blood feeding. The holding cups were 
covered by untreated net with a lateral aspiration hole 
covered with a double layer of dental dam. Blood feed-
ing was done using an inverted cup technique [41]. The 
blood was placed on the bottom surface of a paper cup 
(500  ml capacity) and covered by a thinly stretched 
Parafilm membrane. The membrane was secured with 
masking tape, and the cup was inverted and filled with 
warm water (~ 38 °C). The cups were then held over the 
netting material of the holding cups and mosquitoes 
were allowed to feed. Mosquito feeding was done in the 
dark for a period of 30–60 min. Visually unfed mosqui-
toes were removed and only fully engorged mosquitoes 
kept in the holding cages for follow-up and maintained 
at standard insectary conditions. Mortality was moni-
tored every 24 h for 10 days by counting and removing 
dead mosquitoes. At least three replicates were per-
formed for every drug or drug combination tested. The 
position of the cages was rotated daily.
Data collection and statistical analysis
Daily mortality data were entered in Excel spreadsheets. 
Survival Kaplan–Meier and Cox regression analyses 
were performed in Addinsoft XLSTAT ® version 2018.5 
software (New York, NY, USA) and GNU R (R Core 
Team [2020] R: A language and environment for statis-
tical computing, version 3.6.3, R Foundation for Statisti-
cal Computing, Vienna, Austria, https:// www.R- proje ct. 
org). Comparisons of survival patterns were performed 
with the log-rank test using a 5% significance level. When 
the overall p value was < 0.05, pairwise comparisons were 
performed and Bonferroni correction used to correct for 
multiple comparisons.
Results
Ivermectin induces dose‑dependent but delayed mortality 
in An. gambiae
We first determined the 10-day  LC50 of ivermectin in 
our colony of An. gambiae s.s. The effect of ivermectin 
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on mosquito survival was dose-dependent (Fig.  3). The 
8  ng/ml concentration was the only one that resulted 
in approximately 50% mortality in 10  days, showing a 
mortality rate of 46.49% (Table  2). Therefore, this con-
centration of ivermectin was chosen for use in phase 2 
experiments.
Mortality after ivermectin intake did not occur imme-
diately and was negligible for the first 3 days. Instead, 
mosquito mortality occurred largely between days 4 and 
6. Most of the mosquitoes surviving after day 6 remained 
alive until day 10. These tendencies were observed across 
all the concentrations of ivermectin.
Dual CYP/P‑gp inhibitors have a synergistic effect 
on ivermectin‑induced mosquito mortality
Firstly, we excluded the possibility that any observed dif-
ferences in mortality observed by combining ivermec-
tin with a CYP/P-gp inhibitor were because of additive 
mortality caused by the CYP/P-gp inhibitors themselves. 
No significant differences in mortality were observed 
between mosquitoes that consumed CYP/P-gp inhibitors 
alone and those that did not, irrespective of the dose used 
(Figs. 4a, c, 5a).
In contrast, differences in mortality were observed 
between mosquitoes that consumed ivermectin alone 
and those that consumed ivermectin combined with 
a dual CYP/P-gp inhibitor. Notably, experiments con-
ducted with ritonavir and voriconazole showed enhanced 
ivermectin-induced mortality and dose-dependent syn-
ergism (Fig.  4b, d). Unlike voriconazole, the synergistic 
effect of ritonavir saturated at the second lowest concen-
tration (concentration C). Additionally, when ivermectin 
was combined with ritonavir or voriconazole, an increase 
in the percentage of mortality and decrease in mean sur-
vival time of the mosquitoes were observed (Table 3).
Fig. 1 Schematic representation of phase 1 experiments. Dose-finding study for ivermectin’s 10-day insecticidal concentration  LC50 in our 
Anopheles gambiae s.s. colony.  LC50: insecticidal concentration 50
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Cobicistat, a strong antagonistic effect
Cobicistat alone had no effect on mosquito mortality 
regardless of the concentration used (Fig.  5a). Despite 
being a dual CYP/P-gp inhibitor, cobicistat showed an 
antagonistic effect on ivermectin-induced mortality 
when combined with ivermectin. High cobicistat con-
centrations protected the mosquitoes from ivermec-
tin toxicity, with a higher survival probability recorded 
in cobicistat combined with ivermectin than ivermec-
tin alone (Fig.  5b). Additionally, when combined with 
ivermectin, cobicistat showed a lower percentage of mor-
tality in comparison to ivermectin alone (Table 3).
Inhibition of P‑gp alone does not affect ivermectin‑induced 
mosquito mortality
After observing the effect of CYP/P-gp inhibition on iver-
mectin-induced mortality, we next assessed the effects 
of only inhibiting P-gp transporters. For this, we used 
elacridar and cyclosporine A, which are predominantly 
P-gp inhibitors in  vivo. Similarly to the dual CYP/P-gp 
Fig. 2 Schematic representation of phase 2 experiments. Assessment of 10-day mosquito mortality after feeding on blood containing different 
concentrations of CYP/P-gp inhibitors and inducers, either alone or in combination with ivermectin at the 10-day  LC50 dose determined in phase 1
Table 1 Synergists and corresponding doses used for the experiments
a With effect markedly skewed towards CYP inhibition
b Negligible effect on CYPs
Drug Mechanism of action DA (Cmax) (ng/ml) DB (75% of Cmax) 
(ng/ml)
DC (50% of Cmax) 
(ng/ml)
DD (25% of 
Cmax) (ng/
ml)
Cobicistat [31] Dual CYP/P-gp  inhibitora 990 742 495 247
Cyclosporine A [32] Selective P-gp  inhibitorb 1802 1351 901 450
Elacridar [33] Selective P-gp inhibitor 160 120 80 40
Rifampicin [34] Dual CYP/P-gp inducer 7000 5250 3500 1750
Ritonavir [35] Dual CYP/P-gp inhibitor 11,000 8250 5500 2750
Voriconazole [36] Dual CYP/P-gp inhibitor 3667 2750 1833 916
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inhibitors, the selective P-gp inhibitors alone did not 
cause significant mortality at any dose tested (Fig. 6a, c).
Moreover, when combined with ivermectin, both 
elacridar and cyclosporine A showed no effect on iver-
mectin-induced mortality, suggesting that P-gp inhibitors 
do not synergize with ivermectin to increase mortality 
(Fig. 6b, d).
Simultaneous induction of cytochrome P450 and P‑gp 
may confer modest protection from ivermectin‑induced 
mortality
No significant difference was observed in the survival of 
mosquitoes feeding on rifampicin alone at the different 
doses tested (Fig. 7a).
However, when combined with ivermectin, rifampicin 
at a concentration close to 50% of its Cmax for CYP 3A4 
induction showed a statistically significant difference 
from ivermectin alone; this was seen as antagonism by 
reducing the ivermectin-induced mortality (Table  3; 
Fig. 7b).
Discussion
Susceptibility to ivermectin has been shown to vary 
among mosquito species as well as among mosquito 
strains of the same species [27, 42, 43]. Depending on the 
time frame during which survival is monitored, An. gam-
biae have shown an  LC50 of 19.8, 15.9, and 22.4  ng/ml 
when survival is monitored for 9, 7, and 5 days, respec-
tively [27, 44, 45]. In our case, by monitoring survival for 
10 days, we achieved 46.49% mortality with a concentra-
tion of 8  ng/ml. Though the levels of ivermectin in the 
blood drop rapidly, a concentration above 8 ng/ml can be 
maintained for close to 36 h following an ivermectin dose 
in humans [14, 27]. Our results are aligned with those of 
Smit et  al., in which even very low ivermectin concen-
trations increased mosquito mortality if the follow-up 
period encompassed the usual lifespan [46].
At the doses used, ivermectin-induced mortality 
in mosquitoes was not observed until 2–3  days post-
exposure. One potential explanation for this is the time 
taken for ivermectin to be absorbed from the midgut, as 
faster lethality onset has been observed when ivermec-
tin is injected directly into the midgut than when it is 
taken as part of a blood meal [42]. The second plausible 
explanation for the delayed mortality is the involvement 
of ivermectin metabolites rather than the parent com-
pound in causing mosquito mortality. There is accumu-
lating evidence suggesting the involvement of ivermectin 
metabolites in mosquito mortality, though the specific 
metabolites are yet to be identified [46, 47]. However, 
even before the onset of lethality that is measurable with 
a 10-day follow up, ivermectin can potentially affect mos-
quito mortality in the wild due to its effects on locomo-
tion [48]. Simultaneously, a reduction in locomotion 
ability would affect the vectorial capacity regardless of 
mosquito mortality, which could in turn further reduce 
malaria transmission.
Ivermectin-induced mortality is greatly dependent on 
attaining high systemic levels of ivermectin in the mos-
quito. The exposure to ivermectin is determined by the 
mosquito’s detoxification capacity. Generally, in insects, 
detoxification processes involve metabolic enzymes 
such as CYP, esterase, and glutathione-S-transferases 
(GSTs) together with efflux pumps like the P-gp [49]. In 
this study, we investigated whether and how CYPs and 
P-gp transporters affected ivermectin-induced mor-
tality in mosquitoes. Our results demonstrate that the 
simultaneous inhibition of CYPs and P-gp transporters 
Fig. 3 Ivermectin induces dose-dependent but delayed mortality 
in An. gambiae. Daily survival probability for An. gambiae mosquitoes 
after ingesting blood containing different concentrations of 
ivermectin. Table shows pairwise comparisons of survival in 
different concentrations, with significance level indicated: **p < 0.01, 
***p < 0.001. The 10-day  LC50 is between 8 and 12 ng/ml for this strain 
in this insectary




Mean survival time (95% CI) 10-day % 
mortality
0 (control) 8.1 (7.6–8.5) 20
4 8.1 (7.5–8.6) 38.1
8 7.3 (6.8–7.9) 46.5
12 6.0 (5.5–6.5) 71.1
16 5.6 (5.2–6.1) 75.4
20 4.5 (4.1–4.9) 88.5
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Fig. 4 Synergistic effect of dual CYP/ P-gp inhibitors on ivermectin-induced mosquito mortality. Daily survival probability of An. gambiae 
mosquitoes after imbibing blood containing (a) varied concentrations of ritonavir (RIT), (b) ivermectin (IVM) mixed with varied concentrations of 
ritonavir, (c) varied concentrations of voriconazole, and (d) ivermectin mixed with varied concentrations of voriconazole. When the overall p value 
was < 0.05, pairwise comparisons was performed and the significance level indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Concentration A > B > C > D
Fig. 5 Cobicistat appears to antagonize the ivermectin-induced mosquito mortality. Daily survival probability of An. Gambiae mosquitoes after 
ingesting blood containing (a) varied concentrations of cobicistat (COB), and (b) ivermectin (IVM) mixed with varied concentrations of cobicistat. 
When the overall p value was < 0.05, pairwise comparisons were performed and the significance level indicated: *p < 0.05, **p < 0.01, ***p < 0.001. 
Concentration A > B > C > D
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enhances ivermectin-dependent mortality in a dose-
dependent manner, indicating synergism. However, 
this only happened selectively when ritonavir or vori-
conazole was used. Unexpectedly, the use of cobicistat, 
which is also a dual CYP/P-gp inhibitor, rendered some 
protection from ivermectin. Cobicistat is a structural 
analogue of ritonavir, but unlike ritonavir, which is 
known to inhibit and induce multiple CYPs, cobicistat 
more selectively inhibits CYP3A4 [50]. Though ritona-
vir and cobicistat are considered clinically equivalent, 
the small difference in ritonavir’s ability to induce CYPs 
could result in differences in the drug–drug interaction 
[51, 52]. The induction of CYPs could possibly lead to 
ivermectin metabolism, making ivermectin metabolites 
available.
Despite dual CYP/P-gp inhibitors showing an effect on 
ivermectin-induced mortality, P-gp selective inhibitors did 
not have a measurable effect. Taken together, our results 
suggest that detoxification mechanisms mediated by CYPs 
are more important in ivermectin detoxification. This is 
contrary to what has been reported in mosquito larval 
stages, where Buss et  al. demonstrated that inhibition of 
P-gp using verapamil led to increased toxicity in Culex 
mosquitoes [23]. Collectively, both findings suggest het-
erogeneity in detoxification mechanisms in different stages 
of mosquito development. As a holometabolous insect, the 
changes between the immature stages (larvae and pupae) 
and the adult stage are characterized by differences in diet, 
habitat, morphology, physiology, and behavior. These dif-
ferences could potentially lead to differences in evolution 
of protective mechanisms [53]. Larval stages are known to 
be more prone to developing insecticide resistance com-
pared to the adult stage [53]. Whether the P-gp-mediated 
detoxification reported in Culex larvae is additive or alter-
native to CYP-mediated detoxification in larvae merits 
investigation. Larval habitats are often exposed to iver-
mectin through contamination of aquatic habitats with 
excreta from treated livestock. The stability of ivermectin 
in water for long periods increases the exposure of the 
larvae to ivermectin and could potentially accelerate the 
development of resistance [54]. It is important to under-
stand the mechanisms behind larval resistance to ivermec-
tin and whether they contribute to ivermectin resistance in 
adults.
Our results warrant the investigation of selective CYP 
inhibitors for the ability to synergize ivermectin-induced 
mortality, including molecules susceptible to administra-
tion by contact such as piperonyl butoxide (PBO). This will 
help answer the question of whether CYP inhibition inde-
pendent of P-gp inhibition could still have practical impli-
cations. Notably, the current recommendation for tackling 
metabolic resistance to insecticides is the use of PBO [55]. 
PBO, which is an inhibitor of CYP450 enzymes and is cur-
rently in use by incorporation into pyrethroid long-lasting 
insecticidal nets (LLINs), could also enhance ivermectin-
induced mortality. However, it must be first determined 
whether it synergizes ivermectin-induced mortality.
Table 3 Synergist drugs combined with ivermectin










 Control 8.5 (8.0–9.1) 21.9
 Ivermectin 8.0 (7.5–8.5) 35.0
 IVM + VOR A 3667 5.4 (4.9–5.9) 59.8
 IVM + VOR B 2750 5.7 (5.3–6.0) 44.9
 IVM + VOR C 1833 7.6 (7.0–8.1) 42.2
 IVM + VOR D 916 7.4 (6.9–7.8) 34.7
Ritonavir
 Control 8.0 (7.5–8.4) 18.3
 Ivermectin 8.2 (7.7–8.8) 30.3
 IVM + RIF A 11,000 6.8 (6.1–7.5) 53.7
 IVM + RIF B 8250 6.6 (5.8–7.4) 51.8
 IVM + RIF C 5500 6.7 (6.1–7.3) 55.2
 IVM + RIF D 2750 7.3 (6.7–8.0) 42.3
Cobicistat
 Control 7.1 (6.8–7.5) 18.5
 Ivermectin 7.8 (7.1–8.4) 45.6
 IVM + COB A 990 8.6 (8.1–9.1) 23.6
 IVM + COB B 742 8.2 (7.8–8.7) 29.6
 IVM + COB C 495 7.5 (6.9–8.1) 39.0
 IVM + COB D 247 8.1 (7.6–8.6) 30.8
Elacridar
 Control 9.5 (9.3–9.8) 12.2
 Ivermectin 7.1 (6.5–7.6) 54.6
 IVM + ELA A 160 6.9 (6.4–7.4) 62.3
 IVM + ELA B 120 7.3 (6.8–7.8) 49.6
 IVM + ELA C 80 6.5 (6.1–7.0) 51.4
 IVM + ELA D 40 7.0 (6.5–7.4) 56.1
Cyclosporine A
 Control 9.0 (8.3–9.6) 15.6
 Ivermectin 9.0 (8.5–9.6) 21.8
 IVM + CYC A 1802 7.8 (6.8–8.8) 34.7
 IVM + CYC B 1351 7.7 (6.8–8.6) 38.1
 IVM + CYC C 901 7.7 (7.0–8.4) 20.9
 IVM + CYC D 450 8.5 (7.9–9.2) 33.3
Rifampicin
 Control 7.2 (6.6–7.7) 39.1
 Ivermectin 6.7 (6.0–7.5) 53.4
 IVM + RIF A 7000 6.9 (6.2–7.6) 49.5
 IVM + RIF B 5250 6.4 (5.6–7.1) 61.3
 IVM + RIF C 3500 8.2 (7.6–8.9) 31.5
 IVM + RIF D 1750 6.4 (5.8–7–0) 66.3
Page 9 of 12Nicolas et al. Parasites Vectors          (2021) 14:172  
Fig. 6 Inhibition of P-gp alone does not affect ivermectin-induced mosquito mortality. Daily survival probability of An. Gambiae mosquitoes after 
ingesting blood containing (a) varied concentrations of cyclosporine A (CYC), (b) ivermectin (IVM) mixed with varied concentrations of cyclosporine 
A, (c) varied concentrations of elacridar (ELA), and (d) ivermectin mixed with varied concentrations of elacridar. When the overall p value was < 0.05, 
pairwise comparisons were performed and the significance level indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Concentration A > B > C > D
Fig. 7 Simultaneous induction of cytochrome P450 and P-gp transporters may confer modest protection from ivermectin-induced mortality. Daily 
survival probability of An. Gambiae mosquitoes after ingesting blood containing (a) varied concentrations of rifampicin (RIF) and (b) ivermectin 
(IVM) mixed with varied concentrations of rifampicin. When the overall p value was < 0.05, pairwise comparisons were performed and the 
significance level indicated: *p < 0.05, **p < 0.01, ***p < 0.001. Concentration A > B > C > D
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Limitations of this work include the following: (1) The 
ivermectin concentration used for the combined experi-
ments did not quite yield 50% mortality in 10  days, but 
only 46%. (2) The initial solutions of synergistic molecules 
were prepared using small quantities of DMSO and then 
diluted in PBS to the desired concentration. The control 
solution did not contain DMSO, as previous experiments 
have shown that it does not alter mosquito survival at 
low concentrations [27]. (3) It is still unclear whether the 
finding that only one rifampicin concentration demon-
strated an interaction with ivermectin is an artifact or an 
effect limited to a certain concentration range, and (4) it 
is also unclear why ritonavir and cobicistat interacted in 
such different ways with ivermectin when both molecules 
strongly inhibit CYP 3A4. Still, the involvement of CYPs 
in ivermectin metabolism could potentially lead to cross-
resistance between ivermectin and current insecticides 
used in vector control. Deus et  al. previously demon-
strated that pyrethroid-resistant Ae. aegypti have higher 
tolerance to ivermectin [43]. This could potentially affect 
ivermectin susceptibility in mosquito populations already 
showing metabolic resistance to insecticides, and high-
lights the need to investigate the impact of insecticide 
resistance on susceptibility to ivermectin.
Nevertheless, ivermectin remains a good alternative 
for mosquito populations whose mode of resistance is 
via point mutations, since this resistance mechanism is 
not analogous between the current insecticides and iver-
mectin [56]. While resistance to insecticides is caused by 
mutations in the sodium channel, acetylcholinesterase, or 
gamma-aminobutyric acid (GABA) receptor genes, iver-
mectin resistance in other arthropods is associated with 
mutations involving the glutamate-gated chloride chan-
nels (GluCls) [57, 58].
In the case where ivermectin is to be used in mosquito 
populations with metabolic resistance to the current 
insecticides, our study provides insights into the possi-
bility of ivermectin cross-resistance with other insecti-
cides. Our results suggest that detoxification mechanisms 
mediated by CYPs are more important in ivermectin 
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